For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

GLP-1 / Metabolic

Tirzepatide

Also known as: Tirzepatide (GIP/GLP-1 dual receptor agonist — Mounjaro, Zepbound)

Tirzepatide is a unimolecular dual GIP and GLP-1 receptor agonist with a half-life of approximately 5 days, enabling once-weekly subcutaneous dosing. It is FDA-approved as Mounjaro for type 2 diabetes (2022), Zepbound for chronic weight management in adults with obesity or overweight with a weight-related comorbidity (2023), and Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity (2024). It carries a BOXED WARNING for thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Where to buy · live market data

Who's worth your money for Tirzepatide

Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.

Top Merit pick

Highest Merit Score (99) of 26 scored sellers

$1.50/mg

$1800 · 1200mg · 99.1% purity

Best value

Lowest $/mg among scored sellers

$0.50/mg

$10.00 · 20mg · 99.8% purity

Most tested

57 independent COAs on file

$3.95/mg

$158 · 40mg · 99.9% purity

Average price

$4.03/mg

Sellers

48

45-day trend

-2.5%

42 of 48 sellers have a current price· 5 stale hidden· 11 unverified hidden

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Watch Tirzepatide

Get one email when the market actually moves — no newsletter, no noise.

Compound reference

About Tirzepatide

CAS

2023788-19-2

Molecular formula

C225H348N48O68

Sequence

YXEGTFTSDYSIXLDKIAQKAFVQWLIAGGPSSGAPPPSamide

Typical dose range

2.5–15 mg once weekly subcutaneous injection (research studies mirror clinical titration: start 2.5 mg/week, escalate by 2.5 mg every 4 weeks to max 15 mg/week)

Half-life

~5 days (~120 hours)

Independent evidence

COAs for Tirzepatide

478 third-party tests across 56 vendors. Each card links to the full report.

All 478 COAs for Tirzepatide →
Measured purity 82.3%–100.0% across 311 COAs
Measured purity over time
✓ Vendor-published
99.57 %
Oct 2026
Kovera Labs

For

Tirzeppatide

by Reta One Labs· batch TZ201026

COA on file
Aggregated · 3rd-party listing
99.68 %
Sep 2026
ILS Labs Strong

For

Tirzepatide

by NG Peptide· batch TRZ60-05

Aggregated · 3rd-party listing
99.85 %
Aug 2026
Freedom Diagnostics Moderate

For

Tirzepatide

by VoriLabs· batch TR60-2608-B

Aggregated · 3rd-party listing
99.68 %
Aug 2026
Freedom Diagnostics Moderate

For

Tirzepatide

by VoriLabs· batch TR60-2608-A

✓ Vendor-published
99.90 %
Aug 2026
ILS Laboratories

For

Tirzepatide

by Sunrise Bioresearch· batch GLP230JUL26-01

COA on file
Aggregated · 3rd-party listing
99.92 %
Aug 2026
MZ Biolabs Moderate

For

Tirzepatide

by Novaglo Research· batch 5001072226TZ

Aggregated · 3rd-party listing
99.92 %
Aug 2026
MZ Biolabs Moderate

For

Tirzepatide

by Novaglo Research· batch 5001572326TZ

Aggregated · 3rd-party listing
99.77 %
Aug 2026
MZ Biolabs Moderate

For

Tirzepatide

by Novaglo Research· batch 5000572226TZ

Aggregated · 3rd-party listing
99.68 %
Aug 2026
ILS Labs Strong

For

Tirzepatide

by NovaForge Labs· batch LOT-TR-QSCT1

Aggregated · 3rd-party listing
99.99 %
Aug 2026
ILS Labs Strong

For

Tirzepatide

by Velora Biolabs· batch VBL-TR10-1

Aggregated · 3rd-party listing
99.97 %
Aug 2026
ILS Labs Strong

For

Tirzepatide

by Velora Biolabs· batch VBL-TR30-1

Aggregated · 3rd-party listing
99.87 %
Aug 2026
ILS Labs Strong

For

Tirzepatide

by Velora Biolabs· batch VBL-TR60-1

Aggregated · 3rd-party listing
99.99 %
Aug 2026
MZ Biolabs Moderate

For

Tirzepatide

by Novaglo Research· batch 5003071726TZ

Aggregated · 3rd-party listing
99.90 %
Jul 2026
Krause Analytical

For

Tirzepatide

by VoriLabs· batch VoriLabs TR60-2607-F

Aggregated · 3rd-party listing
99.90 %
Jul 2026
Finnrick Analytics

For

Tirzepatide

by VoriLabs· batch VoriLabs TR60-2607-D

Aggregated · 3rd-party listing
99.90 %
Jul 2026
Krause Analytical

For

Tirzepatide

by VoriLabs· batch VoriLabs TR60-2607-C

Aggregated · 3rd-party listing
99.88 %
Jul 2026
ILS Labs Strong

For

Tirzepatide

by Crush Research· batch CR-2XAG-60-2607-Purple

Aggregated · 3rd-party listing
100.00 %
Jul 2026
ILS Labs Strong

For

Tirzepatide

by jdbioworks· batch 2026-002

Aggregated · 3rd-party listing
99.81 %
Jul 2026
ILS Labs Strong

For

Tirzepatide

by Artisan Aminos· batch AA-TRZ220-049

✓ Vendor-published
99.59 %
Jul 2026
Kovera Labs

For

Tirzeptide

by Ignite Peptides· batch IP-2607-127

COA on file
✓ Vendor-published
99.51 %
Jul 2026
Kovera Labs

For

Tirzepatide

by Ignite Peptides· batch IP-2607-797

COA on file
Aggregated · 3rd-party listing
99.68 %
Jul 2026
Vanguard Laboratory Strong

For

Tirzepatide

by Certified Peptides· batch TIR070226

Aggregated · 3rd-party listing
99.90 %
Jul 2026
BTLabs Moderate

For

Tirzepatide

by VoriLabs· batch TR60-2606-A

Aggregated · 3rd-party listing
100.00 %
Jul 2026
ILS Labs Strong

For

Tirzepatide

by NG Peptide· batch TRZ40-15

Research depth

23 citations indexed for Tirzepatide

All research on Tirzepatide →

cohort · 2026

Weight-Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort

While GLP-1 and GIP receptor agonists like semaglutide and tirzepatide have revolutionized pharmacologic obesity treatment, metabolic and bariatric surgery (MBS) continues to demonstrate superior weight loss and cost-effectiveness.

animal · 2026

Tirzepatide alleviates hepatic steatosis and inflammation in MASLD partly through suppression of macrophage Dectin-1/Syk/NF-κB signaling

Metabolic stress, hepatic lipid accumulation, and macrophage-associated sterile inflammation are closely involved in the development of metabolic dysfunction-associated steatotic liver disease (MASLD). Tirzepatide improves metabolic outcomes, but its effects on macrophage inflammatory signaling in MASLD remain unclear.

Study · 2026

Tirzepatide Initiation in Lithium-Treated Bipolar Disorder: Renal Biomarker Trajectories and Lithium Safety Signals Over 12 Months in a Real-World Cohort

Objective To assess early renal and lithium-related safety and 12-month renal biomarker trajectories after tirzepatide initiation in lithium-treated adults with bipolar disorder. Methods We retrospectively studied 23 adults at one centre.

Study · 2026

Tirzepatide safety in EudraVigilance: descriptive and disproportionality analysis of preferred terms related to suboptimal treatment outcomes and drug-use-related issues

Objective As obesity and diabetes are on the verge of an alarming growth, so is the use of tirzepatide, a novel dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 (GLP-1) receptor agonist (RA) and currently the most effective weight loss-drug.

Study · 2026

Tirzepatide use in adolescents with metabolic dysfunction‐associated steatotic liver disease (MASLD): A case series

meta-analysis · 2026

Comparative Efficacy of Tirzepatide Versus Semaglutide for Weight Loss in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis of Head-to-Head Studies

This systematic review and meta-analysis aimed to compare the efficacy and safety of tirzepatide versus semaglutide for weight reduction in adults with overweight or obesity. We included randomised controlled trials and observational studies comparing tirzepatide and semaglutide with ≥ 24 weeks of follow-up.